KDR-eiwit (C-His, mens)

KDR

CD309, FLK1, VEGFR, VEGFR2

C-His

< 1.0 EU per μg of the protein as determined by the LAL method

> 95 % as determined by SDS-PAGE. > 90 % as determined by SEC-HPLC.

1.Immobilized Recombinant Human VEGFR2 / Flk-1 / CD309 / KDR Protein (His Tag) (Cat: 10012-H08H) at 2 μg/mL (100 μL/well) can bind Recombinant Human VEGF/VEGFA/VEGF165 Protein (His&AVI Tag), Biotinylated (Cat: 11066-H27H-B), the EC50 is 15-40 ng/mL (QC tested) . 2. Measured by its ability to inhibit the VEGF-dependent proliferation of human umbilical vein endothelial cells (HUVEC) . The ED50 for this effect is typically 10-50μg/mL in the presence of 10 ng/mL recombinant human VEGF165 (Routinely tested) . 3.Immobilized Recombinant Human VEGF121 / VEGF-A Protein (Cat: 10008-HNAH) at 2 μg/mL (100 μL/well) can bind Recombinant Human VEGFR2 / Flk-1 / CD309 / KDR Protein (His Tag) (Cat: 10012-H08H), the EC50 is 121 ng/mL (Routinely tested) . 4.Serial dilutions of Anti-VEGF (Research Grade Bevacizumab Biosimilar) were added into Recombinant Human VEGF/VEGFA/VEGF165 Protein (His&AVI Tag), Biotinylated (Cat: 11066-H27H-B) : Recombinant Human VEGFR2 / Flk-1 / CD309 / KDR Protein (His Tag) (Cat: 10012-H08H) binding reactions. The half maximal inhibitory concentration (IC50) is 0.8 μg/mL (Routinely tested) .

Met1-Glu764

The recombinant human VEGFR2 consists of 756 amino acids and predicts a molecular mass of 84.6 kDa. The apparent molecular mass of human VEGFR2 is approximatly 120-130 in SDS-PAGE under reducing conditions due to glycosylation.

Human